Broadcast Date: 
  • Time: 

High-throughput screening assays can identify small molecule modulators of biochemical activities and interactions from large libraries of active compounds in drug discovery studies. However, traditional high-throughput assays rely on cumbersome labels, such as fluorophores, antibodies, and radioisotopes that can lead to false positives. Label-free formats like mass spectrometry aim to address many of these challenges but they either lack the necessary throughput for large screening campaigns or they sacrifice data quality for speed.

In this GEN webinar, Dr. Zack Gurard-Levin will present a label-free strategy for screening large libraries of small molecules that saves time and keeps projects on budget. He will explain how the SAMDI technology, which combines biochip arrays and MALDI mass spectrometry, can screen millions of candidate compounds against protein and RNA targets rapidly and efficiently. He will also discuss how culturing cells on SAMDI biochips enables the measurement of cellular enzyme activities in a high-throughput, label-free manner. In short, SAMDI mass spec unlocks new possibilities for faster, reliable high-throughput screening in a variety of drug discovery programs.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Zack Gurard-Levin
Zack Gurard-Levin, PhD
Science Director, Discovery
Charles River Laboratories